IGNITE

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 7, 2024
American Academy, Research and development, IGNITE, Publication, Research, TREM2, Microglia, Administration, Patient, Enrollment, Interim, Clinical trial, Completeness, Pharmaceutical industry

WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress.

Key Points: 
  • In addition, two posters highlighting the ILLUMINATE Natural History Study of ALSP and the mechanism of action for iluzanebart were also presented.
  • Next data readout from Phase 2 IGNITE clinical trial on track for third quarter of 2024: The Company is on track to report additional data from its Phase 2 clinical trial evaluating iluzanebart in ALSP in the third quarter of 2024.
  • Research and Development (R&D) Expenses: R&D expenses for the first quarter ended March 31, 2024 were $14.3 million, compared to $13.8 million for the same period in 2023.
  • Net Loss: Loss from operations for the first quarter ended March 31, 2024 were $19.9 million, compared to $19.8 million for the same period in 2023.

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, April 17, 2024
Doctor of Philosophy, Immunotherapy, American Academy, NHS, IGNITE, Safety, University College London, AFL, TREM2, American Academy of Neurology, Microglia, Publication, Clinical professor, AAN, ALSP, MRI, Serum, CSF, Interim, Biomarker, Poster, Cerebrospinal fluid, Deficit spending, Medical imaging

WATERTOWN, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the presentation of multiple oral and poster presentations on the Company’s lead clinical candidate iluzanebart at the 2024 American Academy of Neurology (AAN) Annual Meeting.

Key Points: 
  • “We are excited to see our enthusiasm for iluzanebart matched by clinical leaders in the ALSP community.
  • The interim findings from both the IGNITE Phase 2 and ILLUMINATE Natural History studies support the potential of iluzanebart to become the first, disease-modifying therapy for those living with ALSP,” said Petra Kaufmann, M.D., F.A.A.N, Chief Medical Officer of Vigil.
  • “Both trials have led to an incredible step forward – not only in understanding ALSP disease progression, but also in drawing parallels between biomarkers and correlating clinical outcomes.
  • Data on clinical measures, biomarkers, and MRI from ILLUMINATE were presented at the conference.

Kearney almost doubles sustainability projects, recognized as sustainability leader

Retrieved on: 
Monday, April 15, 2024
Carbon, DEI, IGNITE, Mentorship, Woman, CDP, Female, Airport, Air travel, Platinum, Private sector, Annual report, Government, Aviation, Disability, Renewable energy

Kearney recognized on the annual CDP Climate A List, underlining its commitment to reaching net zero

Key Points: 
  • Kearney recognized on the annual CDP Climate A List, underlining its commitment to reaching net zero
    LONDON, April 15, 2024 /PRNewswire/ -- Global management consultancy Kearney has today launched its Sustainability Report for 2023.
  • This is the fifth annual report revealing how the consultancy has advanced its commitments to its clients, the planet, its people, and communities.
  • "Our founder, Tom Kearney's, principle of "essential rightness" is part of our core philosophy at Kearney.
  • "In 2024, we want to continue to build on our successes and embed sustainability in all we do.

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 26, 2024
Research, Administration, CSF1R, TREM2, MRI, Data analysis, PD, CSF, Magnetic resonance imaging, Patient, Biomarker, Microglia, Osteopontin, Fluid mechanics, IGNITE, Investment, Clinical trial, Pharmacokinetics, Interim, Research and development, Data, FDA, AFL, Pharmaceutical industry

WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent progress.

Key Points: 
  • “Among our many recent milestones, the most significant for Vigil was the positive data readout from our ongoing Phase 2 IGNITE trial and ILLUMINATE Natural History Study.
  • We are also pleased to have enrolled 20 patients in our IGNITE trial, exceeding our target of 15 patients.
  • Cash Position: Cash, cash equivalents, and marketable securities were $117.9 million as of December 31, 2023, compared to $133.6 million as of September 30, 2023.
  • The increase year-over-year was primarily attributable to increases in headcount-related costs and professional service fees to support the Company’s growth.

Insight Partners Launches Second Enterprise Accelerator Program: IGNITE Enterprise Accelerator (IEA)

Retrieved on: 
Tuesday, March 12, 2024
Community, Research, CDO, Partner, Insight Partners, Growth, Zurich Insurance Group, Knowledge, Infrastructure, Enterprise, IGNITE, Ecosystem, IEA, Dawn Foods, Management

NEW YORK, March 12, 2024 /PRNewswire/ -- Global software investor Insight Partners today announces its second Enterprise Accelerator Program, IGNITE Enterprise Accelerator (IEA) and call for applicants.

Key Points: 
  • NEW YORK, March 12, 2024 /PRNewswire/ -- Global software investor Insight Partners today announces its second Enterprise Accelerator Program, IGNITE Enterprise Accelerator (IEA) and call for applicants.
  • Part of Insight Partners' many offerings for its global portfolio of over 500 leading software companies, Insight IGNITE brings 2500+ enterprise tech executives access to our investment and market perspectives, founders across all stages, and a network of peers driving digital change.
  • "Insight Partners is committed to partnering with enterprise technology and business leaders to nurture innovation by sharing perspectives from the cutting edge of the startup ecosystem," said Praveen Akkiraju, Managing Director at Insight Partners.
  • Community Events & Networking: Invitations to exclusive Insight Partners events and networking sessions, facilitating connections with peers and industry experts.

PETPATH AND IGNITE® VETERINARY SOLUTIONS ANNOUNCE INDUSTRY-LEADING MULTIMARKET AGREEMENT COMMERCIALIZING DIGITAL CARE MANAGEMENT

Retrieved on: 
Thursday, January 25, 2024
Learning, Patient, Hospital, Health, Partnership, Pet, Love, App Store (iOS/iPadOS), Caregiver, DVM, Fear, Confusion, MRCVS, CARE, IGNITE, Veterinarian, Growth, Nursing

The companies will initially focus on the specialty services, emergency, and critical care markets, highlighting the critical benefit of digital pet recovery pathways.

Key Points: 
  • The companies will initially focus on the specialty services, emergency, and critical care markets, highlighting the critical benefit of digital pet recovery pathways.
  • "This agreement will be instrumental in driving wide-scale adoption of PetPath," said Alex Ehrich, Co-founder and Director of Partnerships of Pet Path.
  • With PetPath, veterinary teams deliver a better client experience and better pet care through a personalized approach to pet recovery.
  • Importantly, PetPath enables practitioners to adapt the care pathway and customize discharge and recovery guidance to match their individual hospital's protocols.

Canadian Paralympic athletes will receive financial recognition for podium performances

Retrieved on: 
Wednesday, January 24, 2024
Olympic Games, Government, PFC, Athlete, Olympian, History, Work, Sport, International Paralympic Committee, Federation, Gold, CPC, Game, News, IGNITE

The new "Paralympic Performance Recognition" program will reward Paralympians $20,000 for winning a gold medal, $15,000 for a silver medal, and $10,000 for bronze at the Paralympic Games.

Key Points: 
  • The new "Paralympic Performance Recognition" program will reward Paralympians $20,000 for winning a gold medal, $15,000 for a silver medal, and $10,000 for bronze at the Paralympic Games.
  • The Malaviya Foundation's total contribution of $4 million is one of the most significant donations in Canadian Paralympic sport history.
  • "It is fantastic to know that today's Paralympians and the next generation of athletes to come will receive this much-deserved equitable recognition for their performances.
  • The Paralympic Performance Recognition program brings us one step closer to earning the same recognition and respect as our Olympic counterparts."

National Run For Office Day Recruits Gen Z, Other Underrepresented Groups to Run For Office Ahead of 2024 Election

Retrieved on: 
Tuesday, January 23, 2024
Civic, Entrepreneurship, Woman, Democracy, Social media, Generation Z, Senate, Government, Gen, Argent, First Nations in Manitoba, Disability, Run, Nation, IGNITE

WASHINGTON, Jan. 23, 2024 /PRNewswire/ -- Today is National Run For Office Day, an effort led by Civic Nation and Run for Something Civics to increase representation at every level of government. The nonpartisan campaign encourages people who are underrepresented in elected office, including young people, people of color, people who identify as LGBTQIA+ and people with disabilities to run for elected office – especially local offices.

Key Points: 
  • Local elected officials in New York will join a celebration at Argent today to encourage more people to run for office.
  • The event will include giveaways from Glossier, interactive photo opportunities and critical conversations about running for office.
  • That's why Civic Nation is proud to work with Run For Something Civics to lead National Run For Office Day.
  • "National Run For Office Day is more important than ever to ensure government works for everyone, not just those with power and influence."

IGNITE Veterinary Solutions and VerticalVet Establish a Learning Alliance to Elevate Veterinary Practices and Enrich Educational Opportunities

Retrieved on: 
Thursday, January 11, 2024
Workforce, Partnership, GRC, Learning, Education, IGNITE, VRCE, Growth, Management

VerticalVet members will now have privileged access to IGNITE's innovative products, programs, and solutions.

Key Points: 
  • VerticalVet members will now have privileged access to IGNITE's innovative products, programs, and solutions.
  • This means VerticalVet members can now take full advantage of IGNITE's comprehensive educational resources, empowering their teams and enabling them to deliver the highest level of veterinary care.
  • Mark Shaw, CEO of IGNITE Veterinary Solutions, remarked, "We are thrilled to partner with VerticalVet.
  • Through these offerings, IGNITE Veterinary Solutions and VerticalVet are accelerating the growth of the veterinary profession with highly differentiated next-generation learning tools for veterinary teams.

IGNITE® unveils the IGNITE Veterinary Assistant Program: Empowering Veterinary Teams to Deliver Exceptional Practice Performance

Retrieved on: 
Thursday, January 4, 2024
Culture, Health care, Health, Mental health, Animal, IGNITE, Knowledge, Veterinary medicine, Mistake, Curriculum, Communication, Nursing

AUSTIN, Texas, Jan. 4, 2024 /PRNewswire/ -- IGNITE, a leading veterinary learning company, proudly introduces the IGNITE Veterinary Assistant Program (IVAP), a modern skills-based learning program designed to elevate veterinary teams and deliver higher levels of veterinary care.

Key Points: 
  • AUSTIN, Texas, Jan. 4, 2024 /PRNewswire/ -- IGNITE, a leading veterinary learning company, proudly introduces the IGNITE Veterinary Assistant Program (IVAP), a modern skills-based learning program designed to elevate veterinary teams and deliver higher levels of veterinary care.
  • Veterinary teams have trusted IGNITE as a provider of innovative learning content, programs, and tools that enable all roles in the hospital to thrive.
  • IGNITE recognizes that veterinary assistants can and should play a key role in relieving some of these common challenges.
  • The IGNITE Veterinary Assistant Program (IVAP) will help you develop and retain talent, drive a positive client experience, and improve patient care.